case_images: PMC4599040_01
case_images: Computed tomography scan of the lung before and after 14 months of gefitinib treatment.
case_images: ott-8-2739Fig1.jpg
case_images: PMC4599040_01_ott-8-2739Fig1.jpg
case_images: f1-ott-8-2739
case_images: Partial response (PR) was detected, and progression-free survival (PFS) lasted for 14 months (Figure 1).
case_images: Magnetic resonance imaging showing the disappearance of the paraspinal tumor after erlotinib treatment.
case_images: ott-8-2739Fig2.jpg
case_images: PMC4599040_01_ott-8-2739Fig2.jpg
case_images: f2-ott-8-2739
case_images: After the second administration of an EGFR-TKI, the paraspinal tumor disappeared (Figure 2), and tumors in both lungs shrank significantly (Figure 3).
case_images: Computed tomography scan showing that the lung tumor shrank significantly after erlotinib treatment.
case_images: ott-8-2739Fig3.jpg
case_images: PMC4599040_01_ott-8-2739Fig3.jpg
case_images: f3-ott-8-2739
case_images: After the second administration of an EGFR-TKI, the paraspinal tumor disappeared (Figure 2), and tumors in both lungs shrank significantly (Figure 3).